Frank X. Leonard - 28 Feb 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Signature
By: /s/ Steven Robbins, Attorney in Fact for Frank X. Leonard
Issuer symbol
NVCR
Transactions as of
28 Feb 2023
Net transactions value
+$2,255,244
Form type
4
Filing time
02 Mar 2023, 16:01:17 UTC
Previous filing
09 Jan 2023
Next filing
06 Mar 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $0 +18,621 +40% $0.000000 64,779 28 Feb 2023 Direct F1
transaction NVCR Ordinary Shares Sale $128,594 -1,684 -2.6% $76.36 63,095 01 Mar 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Options to Buy Ordinary Shares Award $2,383,838 +30,971 $76.97 30,971 28 Feb 2023 Ordinary Shares 30,971 $76.97 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Options to buy 30,971 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.